Peptide Companion
Peptide Companion
blend
Growth Hormone
Vial: 10 mg

How is CJC-1295 NO DAC + Ipamorelin (10 mg Blend) dosed and mixed?

CJC-1295 NO DAC + Ipamorelin (10 mg Blend) is a peptide blend research reference in the Growth Hormone category for a 10 mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 3.33 mg/mL. The published research schedule lists 0.1–0.2 mg per injection, 2–3 times daily for 8–12 weeks; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS). CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases, while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Dose
0.1–0.2 mg per injection
Frequency
2–3 times daily
Timing
Morning, post-workout, before bed
Duration
8–12 weeks

Short-acting version. Mimics natural GH pulses. Best combined with GHRP peptides.

Dosing Schedule
WeekDaily Dose (mcg each)Units (per injection) (mL)
Weeks 1–2100 mcg each3 units (0.03 mL)
Weeks 3–4150 mcg each4.5 units (0.045 mL)
Weeks 5–6200 mcg each6 units (0.06 mL)
Weeks 7–12250–300 mcg each7.5–9 units (0.075–0.09 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
  • •Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL total concentration (1.67 mg/mL each peptide).
  • •Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
  • •Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
  • •Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Supplies Needed
  • •Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):
  • •Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Benefits
  • •Supports sustained GH and IGF-1 elevation through pulsatile release patterns.
  • •Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation.
  • •Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
  • •Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
  • •Some individuals report increased appetite, water retention, or tingling sensations.
How It Works

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.

References and original studies

  • PubMed

    Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults

    View original study

  • PubMed

    Once-daily CJC-1295 normalizes growth in GHRH knockout mouse

    View original study

  • PubMed

    Ipamorelin, the first selective growth hormone secretagogue

    View original study

  • PMC

    Beyond the androgen receptor: GH secretagogues in body composition management

    View original study

  • PubMed

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers

    View original study

  • PubMed

    Ipamorelin GH pulse kinetics and timing studies

    View original study

  • CDC

    Vaccine administration: subcutaneous route (angle/site; no aspiration)

    View source

  • CDC (Subcut Injection PDF)

    Technique diagram and site guidance for subcutaneous injections

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View original study

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View original study

  • Frontiers in Endocrinology

    Growth hormone secretagogues: history and clinical applications

    View source

  • Endocrine Reviews

    Ghrelin and growth hormone secretagogues: physiology and applications

    View source

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.